FDA OKs OTC Zyrtec-D

Share this article:

The FDA said today it has approved Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg) as an OTC product for adults and children 12 years of age and older.

Zyrtec-D will be distributed by Johnson & Johnson's unit McNeil Consumer Healthcare, which acquired OTC rights to the drug when Pfizer's Consumer Unit was purchased by J&J in 2006 for just over $16 billion.

Zyrtec-D combines the antihistamine, cetirizine, with the nasal decongestant, pseudoephedrine, and is indicated to treat hay fever or other upper respiratory allergies.

Sales of OTC Zyrtec-D will be subject to restrictions implemented under the Combat Methamphetamine Epidemic Act which places restrictions on the sale of products containing pseudoephedrine. Those restrictions include limiting the amount of pseudoephedrine-contatining products an individual can purchase and imposing record-keeping requirements on pharmacy and retail establishments selling the products.

In large amounts, pseudoephedrine can be used to make the illegal drug methamphetamine.
 
Hay fever and other allergies are the sixth leading cause of chronic disease, with about 50 million sufferers in the US, according to the National Institutes of Health.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...